A

Adverum Biotechnologies
D

ADVM

2.26500
USD
-0.23
(-9.22%)
مغلق
حجم التداول
7,919
الربح لكل سهم
-6
العائد الربحي
-
P/E
-0
حجم السوق
47,317,510
أصول ذات صلة
A
ABEO
0.04000
(0.62%)
6.45000 USD
ALNY
ALNY
0.75
(0.26%)
292.46 USD
A
ARWR
-1.020
(-6.25%)
15.290 USD
B
BLUE
-0.01000
(-0.20%)
4.97000 USD
C
CRSP
-2.300
(-5.86%)
36.970 USD
E
EDIT
-0.05500
(-3.53%)
1.50500 USD
R
RCKT
-0.25500
(-3.72%)
6.59500 USD
REGN
REGN
-10.13
(-1.65%)
604.65 USD
S
SRPT
0.485
(1.23%)
40.045 USD
V
VYGR
-0.25500
(-7.50%)
3.14500 USD
المزيد
الأخبار المقالات

العنوان: Adverum Biotechnologies

القطاع: Healthcare
الصناعة: Biotechnology
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.